Novogen is developing new

patient-focused

therapies for cancer that have the potential to make a significant impact

Novogen is a global biotechnology company dedicated to creating sustainable long-term shareholder value through the discovery and development of significant new therapies for patients with cancer.

  • News

    6 December 2016New

    Novogen Enrols First Patient into Phase I Study of CantrixilRead more

    17 November 2016New

    Webcast of Dr James Garner's 2016 AGM presentationRead more

    17 November 2016New

    AGM polling resultsRead more

    More News

  • Upcoming Events

    9-11 January 2017

    9th Annual Biotech Showcase Conference, San Francisco, USA

    Dr James Garner to present on Novogen.

    More Events

  • In-licensing of GDC-0084

    31 October 2016

    Edison research – Novogen Acquires Mid-Stage Cancer Drug from GenentechRead more

    31 October 2016

    In-licensing of GDC-0084Read more

    31 October 2016

    In-licensing of GDC-0084 – Investor PresentationRead more

  • Share Price

    Historical Prices

SITE BY SPATIAL DESIGN